Animal models of osteogenesis imperfecta: applications in clinical research
- PMID: 30774469
- PMCID: PMC6209373
- DOI: 10.2147/ORR.S85198
Animal models of osteogenesis imperfecta: applications in clinical research
Abstract
Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a genetic disease characterized by extreme bone fragility and consequent skeletal deformities. This connective tissue disorder is caused by mutations in the quality and quantity of the collagen that in turn affect the overall mechanical integrity of the bone, increasing its vulnerability to fracture. Animal models of the disease have played a critical role in the understanding of the pathology and causes of OI and in the investigation of a broad range of clinical therapies for the disease. Currently, at least 20 animal models have been officially recognized to represent the phenotype and biochemistry of the 17 different types of OI in humans. These include mice, dogs, and fish. Here, we describe each of the animal models and the type of OI they represent, and present their application in clinical research for treatments of OI, such as drug therapies (ie, bisphosphonates and sclerostin) and mechanical (ie, vibrational) loading. In the future, different dosages and lengths of treatment need to be further investigated on different animal models of OI using potentially promising treatments, such as cellular and chaperone therapies. A combination of therapies may also offer a viable treatment regime to improve bone quality and reduce fragility in animals before being introduced into clinical trials for OI patients.
Keywords: OI; brittle bone; clinical research; dog; mouse; zebrafish.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Similar articles
-
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.Osteoporos Int. 2014 Aug;25(8):2097-107. doi: 10.1007/s00198-014-2737-y. Epub 2014 May 7. Osteoporos Int. 2014. PMID: 24803333 Free PMC article.
-
Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta.Calcif Tissue Int. 2024 Mar 12. doi: 10.1007/s00223-024-01188-2. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38472351 Review.
-
An Update on Animal Models of Osteogenesis Imperfecta.Calcif Tissue Int. 2022 Oct;111(4):345-366. doi: 10.1007/s00223-022-00998-6. Epub 2022 Jun 29. Calcif Tissue Int. 2022. PMID: 35767009 Review.
-
[Osteogenesis imperfecta and achievements in cell and gene therapy].Acta Med Croatica. 2010 Jul;64(3):191-200. Acta Med Croatica. 2010. PMID: 20922862 Review. Croatian.
-
Osteogenesis Imperfecta.2020 Jul 26. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2020 Jul 26. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905334 Free Books & Documents. Review.
Cited by
-
Extra-Skeletal Manifestations in Osteogenesis Imperfecta Mouse Models.Calcif Tissue Int. 2024 Apr 19. doi: 10.1007/s00223-024-01213-4. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38641703
-
Significance of Premature Vertebral Mineralization in Zebrafish Models in Mechanistic and Pharmaceutical Research on Hereditary Multisystem Diseases.Biomolecules. 2023 Nov 6;13(11):1621. doi: 10.3390/biom13111621. Biomolecules. 2023. PMID: 38002303 Free PMC article. Review.
-
Exploration of the skeletal phenotype of the Col1a1 +/Mov13 mouse model for haploinsufficient osteogenesis imperfecta type 1.Front Endocrinol (Lausanne). 2023 Mar 8;14:1145125. doi: 10.3389/fendo.2023.1145125. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36967771 Free PMC article.
-
Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life.Int J Mol Sci. 2022 Dec 22;24(1):184. doi: 10.3390/ijms24010184. Int J Mol Sci. 2022. PMID: 36613624 Free PMC article. Review.
-
Collagen piezoelectricity in osteogenesis imperfecta and its role in intrafibrillar mineralization.Commun Biol. 2022 Nov 11;5(1):1229. doi: 10.1038/s42003-022-04204-z. Commun Biol. 2022. PMID: 36369514 Free PMC article.
References
-
- Baljet B. Aspects of the history of osteogenesis imperfecta (Vrolik’s syndrome) Ann Anat. 2002;184(1):1–7. - PubMed
-
- Kamoun-Goldrat AS, Le Merrer MF. Animal models of osteogenesis imperfecta and related syndromes. J Bone Miner Metab. 2007;25(4):211–218. - PubMed
-
- Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377–1385. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
